Test Catalog

Test Name

Test ID: FPFIB    

Useful For Suggests clinical disorders or settings where the test may be helpful


Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

PROMETHEUS FIBROSpect II testing can aid physicians in differentiating no/mild liver fibrosis from moderate-to-severe liver fibrosis in patients with hepatitis C.  FIBROSpect II is now designed to differentiate between lower-stage (METAVIR F0-F2) and advanced liver fibrosis/cirrhosis (METAVIR F3-F4). Due to sampling error and the relative risk of biopsy, PROMETHEUS FIBROSpect II testing is useful for initial patient evaluation, to reduce the need for liver biopsy, as an adjunct to biopsy and when biopsy is contraindicated or refused.


A quantitative analysis of hyaluronic acid (HA), tissue inhibitor of metalloproteinase (TIMP-1), and a2-macroglobulin (AMG) interpreted utilizing an algorithm to predict with no indeterminate results the likelihood of liver fibrosis in patients with hepatitis C.


Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

A final report will be attached in MayoAccess.

Interpretation Provides information to assist in interpretation of the test results

In a study population of chronic HCV patients (n=696) with a fibrosis (METAVIR F3-F4) prevalence of 31.8%, FIBROSpect II sensitivity at an index of 42 was 80% and the specificity was 76%. Tests performed to determine FIBROSpect II result: alpha-2 macroglobin (AMG) by nephelometry. Tissue inhibitor of metalloproteinases-1 (TIMP-1) by electrochemiluminescence, Hyaluronic acid (HA) by ELISA.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1.)   K. Patel et al., Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41:935-942.

2.)   A. Zaman et al., Assessment of FIBROspect II to Detect Hepatic Fibrosis in Chronic Hepatitis C Patients. Am J Med 2007; 120:280.e9-280.e14.

3.)   C. Christensen et al., Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepatitis 2006; 13:652-658.

4.)   K. Patel et al., Correlation of FIBROSpect II With Histologic and Morphometric Evaluation of Liver Fibrosis in Chronic Hepatitis C. Clin Gastroenterol H 2008; 6:242-247.

5.)   K. Patel et al., An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepatitis 2009; 16:178-186.

6.)   Data on file. Prometheus Laboratories Inc. DOF 16-001, 01/2016